Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 9/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | USP2 | O75604 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119751 | 0.81 | MEN1 (0.44) | SMN1; SMN2ALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL3113286 | 0.81 | CYP1A2 (0.70) | SMN1; SMN2ALDH1A1KMT2AKDM4ENPSR1 | |
| SCHEMBL15756676 | 0.80 | TSHR (0.55) | SMN1; SMN2ALDH1A1KMT2AKDM4ENPSR1 | |
| SCHEMBL6739809 | 0.76 | GAA (0.58) | SMN1; SMN2ALDH1A1KMT2AKDM4ENPSR1 | |
| SCHEMBL20119891 | 0.76 | APP (0.48) | KMT2ATSHRLMNACLK4MEN1 | |
| SCHEMBL29019912 | 0.74 | CYP1A2 (0.58) | SMN1; SMN2ALDH1A1KMT2AKDM4ENPSR1 | |
| SCHEMBL30395412 | 0.74 | CYP1A2 (0.58) | SMN1; SMN2ALDH1A1KMT2AKDM4ENPSR1 | |
| SCHEMBL27228484 | 0.74 | LMNA (0.40) | LMNACLK4CLK2AURKB | |
| SCHEMBL20119845 | 0.74 | APP (0.44) | SMN1; SMN2ALDH1A1KDM4ECLK4HPGD | |
| SCHEMBL20119610 | 0.73 | JAK2 (0.51) | SMN1; SMN2ALDH1A1KMT2AKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | SMN1; SMN2 11/4885ALDH1A1 2393/4885KMT2A 2971/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | SMN1; SMN2 11/4885ALDH1A1 2393/4885KMT2A 2971/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | SMN1; SMN2 11/4885ALDH1A1 2393/4885KMT2A 2971/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | SMN1; SMN2 11/4885ALDH1A1 2393/4885KMT2A 2971/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | SMN1; SMN2 11/4885ALDH1A1 2393/4885KMT2A 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.